LPRS3
MCID: LPR021
MIFTS: 69

Leprosy 3 (LPRS3)

Categories: Eye diseases, Genetic diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases, Reproductive diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Leprosy 3

MalaCards integrated aliases for Leprosy 3:

Name: Leprosy 3 56 29 6
Leprosy 56 12 74 25 58 43 15 17 71
Leprosy, Susceptibility to 56 13
Infection Due to Mycobacterium Leprae 25
Leprosy, Susceptibility to, 3 56
Hansen's Disease 25
Leprosy, Type 3 39
Hansen Disease 25
Lprs3 56

Characteristics:

Orphanet epidemiological data:

58
leprosy
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Worldwide); Age of onset: All ages; Age of death: any age;

OMIM:

56
Inheritance:
autosomal dominant

Miscellaneous:
see for a discussion on leprosy susceptibility



Classifications:

Orphanet: 58  
Rare neurological diseases
Rare infertility disorders
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1024
OMIM 56 246300
ICD9CM 34 030
MeSH 43 D007918
NCIt 49 C84824
SNOMED-CT 67 81004002
ICD10 32 A30 A30.9
MESH via Orphanet 44 D007918
UMLS via Orphanet 72 C0023343
Orphanet 58 ORPHA548
MedGen 41 C1968668
SNOMED-CT via HPO 68 258211005 263681008
UMLS 71 C0023343

Summaries for Leprosy 3

Genetics Home Reference : 25 Leprosy, also called Hansen disease, is a disorder known since ancient times. It is caused by bacteria called Mycobacterium leprae and is contagious, which means that it can be passed from person to person. It is usually contracted by breathing airborne droplets from affected individuals' coughs and sneezes, or by coming into contact with their nasal fluids. However, it is not highly transmissible, and approximately 95 percent of individuals who are exposed to Mycobacterium leprae never develop leprosy. The infection can be contracted at any age, and signs and symptoms can take anywhere from several months to 20 years to appear. Mycobacterium leprae Mycobacterium leprae Leprosy affects the skin and the peripheral nerves, which connect the brain and spinal cord to muscles and to sensory cells that detect sensations such as touch, pain, and heat. Most affected individuals have areas of skin damage (cutaneous lesions) and problems with nerve function (peripheral neuropathy); however, the severity and extent of the problems vary widely. Leprosy occurs on a spectrum, in which the most severe form is called multibacillary or lepromatous, and the least severe form is called paucibacillary or tuberculoid. Patterns of signs and symptoms intermediate between these forms are sometimes called borderline forms. Multibacillary leprosy usually involves a large number of cutaneous lesions, including both surface damage and lumps under the skin (nodules). The moist tissues that line body openings such as the eyelids and the inside of the nose and mouth (mucous membranes) can also be affected, which can lead to vision loss, destruction of nasal tissue, or impaired speech. Some affected individuals have damage to internal organs and tissues. The nerve damage that occurs in multibacillary leprosy often results in a lack of sensation in the hands and feet. Repeated injuries that go unnoticed and untreated because of this lack of sensation can lead to reabsorption of affected fingers or toes by the body, resulting in the shortening or loss of these digits. Paucibacillary leprosy typically involves a small number of surface lesions on the skin. There is generally loss of sensation in these areas, but the other signs and symptoms that occur in multibacillary leprosy are less likely to develop in this form of the disorder. In any form of leprosy, episodes called reactions can occur, and can lead to further nerve damage. These episodes can include reversal reactions, which involve pain and swelling of the skin lesions and the nerves in the hands and feet. People with the more severe forms of leprosy can develop a type of reaction called erythema nodosum leprosum (ENL). These episodes involve fever and painful skin nodules. In addition, painful, swollen nerves can occur. ENL can also lead to inflammation of the joints, eyes, and the testicles in men. Leprosy has long been stigmatized because of its infectious nature and the disfigurement it can cause. This stigma can cause social and emotional problems for affected individuals. However, modern treatments can prevent leprosy from getting worse and spreading to other people. While the infection is curable, nerve and tissue damage that occurred before treatment is generally permanent.

MalaCards based summary : Leprosy 3, also known as leprosy, is related to borderline leprosy and tuberculoid leprosy, and has symptoms including skin lesions, sensory loss and motor loss. An important gene associated with Leprosy 3 is TLR2 (Toll Like Receptor 2), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Dapsone and Rifampicin have been mentioned in the context of this disorder. Affiliated tissues include superficial peripheral nerves, skin and mucous membranes of the upper respiratory tract, and related phenotypes are blindness and muscle weakness

Disease Ontology : 12 A primary bacterial infectious disease that results in infection located in superficial peripheral nerves, located in skin, located in mucous membranes of the upper respiratory tract, located in anterior chamber of the eyes, or located in testes, has material basis in Mycobacterium leprae, which is transmitted by aerosol spread from infected nasal secretions to exposed nasal and oral mucosa. The infection has symptom skin lesions, has symptom sensory loss, has symptom motor loss and has symptom eye damage.

Wikipedia : 74 Leprosy, also known as Hansen's disease (HD), is a long-term infection by the bacteria Mycobacterium... more...

More information from OMIM: 246300

Related Diseases for Leprosy 3

Diseases in the Leprosy 3 family:

Leprosy 2 Leprosy 1
Leprosy 4 Leprosy 5
Leprosy 6

Diseases related to Leprosy 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1129)
# Related Disease Score Top Affiliating Genes
1 borderline leprosy 35.3 SDHD MLLT1 CD40LG CCDC122
2 tuberculoid leprosy 35.2 TLR2 SDHD IL2 IL10 IFNG CD40LG
3 indeterminate leprosy 35.2 SLC11A1 SDHD PACRG MLLT1 CD40LG CCDC122
4 buruli ulcer 33.4 SLC11A1 IL10 IFNG
5 neuritis 32.3 TNF IL10 IFNG
6 syphilis 31.8 TNF IFNG CD8A CD40LG CD4 CCR6
7 leishmaniasis 31.8 TNF TLR2 SLC11A1 IL2 IL10 IFNG
8 allergic hypersensitivity disease 31.7 TNF IL2 IL10 IFNG CD4 CCR6
9 iridocyclitis 31.7 TNF IL10 CD40LG CD4
10 mycobacterium tuberculosis 1 31.7 TNF TLR2 SLC11A1 NOD2 IL10 IFNG
11 uveitis 31.6 TNF NOD2 IL2 IL10 IFNG
12 keratitis, hereditary 31.6 TNF TLR2 CD4 CCR6
13 skin disease 31.5 TNF TLR2 IL2 IL10 IFNG CD8A
14 sarcoidosis 1 31.5 TNF SLC11A1 NOD2 IL2 IFNG CD8A
15 scabies 31.5 IL10 CD4 CCR6
16 mononeuritis multiplex 31.5 TNF CD40LG CD4
17 cutaneous leishmaniasis 31.5 TNF TLR2 SLC11A1 IL2 IL10 IFNG
18 chronic granulomatous disease 31.5 TNF SLC11A1 LACC1 IFNG CD40LG
19 facial paralysis 31.5 CD8A CD40LG CD4
20 peripheral nervous system disease 31.4 TNF TLR2 SDHD PRKN MLLT1 LRRK2
21 autoimmune disease 31.4 TNF SLC11A1 IL2 IL10 IFNG CD40LG
22 immune deficiency disease 31.4 TNF TLR2 IL2 IL10 IFNG CD40LG
23 arthritis 31.4 TNF TLR2 SLC11A1 NOD2 LACC1 IL10
24 iritis 31.3 TNF NOD2 CD8A CD40LG CD4 CCR6
25 tetanus 31.3 TNF IL2 IL10 IFNG CD40LG
26 exanthem 31.3 TNF IL2 IL10 IFNG CD8A CD40LG
27 psoriasis 31.3 TNF TLR2 NOD2 IL2 IL10 IFNG
28 tenosynovitis 31.3 TNF NOD2 CD40LG
29 dermatitis 31.3 TNF NOD2 IL2 IL10 IFNG CCR6
30 filariasis 31.3 TNF TLR2 IL2 IL10 IFNG
31 human immunodeficiency virus type 1 31.2 TNF IL2 IL10 IFNG CD4
32 skin sarcoidosis 31.2 TNF IL2 CD8A CD4
33 osteomyelitis 31.2 TNF TLR2 NOD2 IL10 IFNG
34 vitiligo-associated multiple autoimmune disease susceptibility 1 31.2 IL2 CD8A CD4 CCR6
35 visceral leishmaniasis 31.2 TNF TLR2 SLC11A1 IL2 IL10 IFNG
36 granulomatous dermatitis 31.2 TNF NOD2 CD40LG CD4
37 erythema multiforme 31.1 TNF IL2 IFNG
38 secondary syphilis 31.1 CD8A CD40LG CD4
39 conjunctivitis 31.1 TNF IL2 IL10 IFNG
40 sporotrichosis 31.1 IL10 IFNG CD40LG CD4
41 scleritis 31.1 TNF IFNG CCR6
42 norwegian scabies 31.1 CD8A CD40LG CD4
43 plague 31.1 TNF TLR2 IL10 CD8A CD4
44 filarial elephantiasis 31.1 TLR2 IL10 CD4
45 proteasome-associated autoinflammatory syndrome 1 31.1 TNF TLR2 IL10 IFNG
46 lymphadenitis 31.1 TNF SLC11A1 NOD2 IL10 IFNG CD4
47 mucocutaneous leishmaniasis 31.0 TNF IL2 IL10 IFNG CD8A CD4
48 periodontitis 31.0 TNF TLR2 IL10 IFNG
49 lymphopenia 31.0 IL2 IL10 IFNG CCR6
50 pfeiffer syndrome 31.0 IL2 CD8A CD40LG CD4 CCR6

Comorbidity relations with Leprosy 3 via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Leprosy 3:



Diseases related to Leprosy 3

Symptoms & Phenotypes for Leprosy 3

Human phenotypes related to Leprosy 3:

58 31 (show all 47)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 blindness 58 Very rare (<4-1%)
2 muscle weakness 58 Occasional (29-5%)
3 peripheral neuropathy 58 Very frequent (99-80%)
4 skeletal muscle atrophy 58 Frequent (79-30%)
5 hyperkeratosis 58 Frequent (79-30%)
6 hypohidrosis 58 Frequent (79-30%)
7 alopecia 58 Occasional (29-5%)
8 glaucoma 58 Very rare (<4-1%)
9 abnormality of the immune system 31 HP:0002715
10 abnormality of the adrenal glands 58 Very rare (<4-1%)
11 uveitis 58 Very rare (<4-1%)
12 paresthesia 58 Frequent (79-30%)
13 epistaxis 58 Occasional (29-5%)
14 gynecomastia 58 Very rare (<4-1%)
15 sparse body hair 58 Frequent (79-30%)
16 abnormality of the spleen 58 Very rare (<4-1%)
17 abnormality of the liver 58 Very rare (<4-1%)
18 steppage gait 58 Occasional (29-5%)
19 corneal ulceration 58 Occasional (29-5%)
20 abnormality of bone marrow cell morphology 58 Very rare (<4-1%)
21 constrictive median neuropathy 58 Occasional (29-5%)
22 impaired temperature sensation 58 Frequent (79-30%)
23 absent eyebrow 58 Occasional (29-5%)
24 skin nodule 58 Frequent (79-30%)
25 autoamputation of digits 58 Occasional (29-5%)
26 verrucous papule 58 Occasional (29-5%)
27 foot dorsiflexor weakness 58 Occasional (29-5%)
28 facial shape deformation 58 Occasional (29-5%)
29 iritis 58 Very rare (<4-1%)
30 loss of eyelashes 58 Occasional (29-5%)
31 decreased corneal sensation 58 Occasional (29-5%)
32 corneal perforation 58 Very rare (<4-1%)
33 acute episodes of neuropathic symptoms 58 Frequent (79-30%)
34 abnormal autonomic nervous system physiology 58 Frequent (79-30%)
35 enlarged peripheral nerve 58 Frequent (79-30%)
36 abnormality of the upper respiratory tract 58 Occasional (29-5%)
37 entrapment neuropathy 58 Frequent (79-30%)
38 hyperalgesia 58 Occasional (29-5%)
39 acral ulceration 58 Frequent (79-30%)
40 dissociated sensory loss 58 Frequent (79-30%)
41 hypopigmented macule 58 Frequent (79-30%)
42 penetrating foot ulcers 58 Occasional (29-5%)
43 abnormality of the seventh cranial nerve 58 Occasional (29-5%)
44 abnormality of facial skeleton 58 Occasional (29-5%)
45 paralytic lagophthalmos 58 Occasional (29-5%)
46 urticarial plaque 58 Occasional (29-5%)
47 testicular mass 58 Very rare (<4-1%)

Symptoms via clinical synopsis from OMIM:

56
Immunology:
susceptibility to infection by mycobacterium leprae causing leprosy

Clinical features from OMIM:

246300

Symptoms:

12
  • skin lesions
  • sensory loss
  • motor loss
  • eye damage

MGI Mouse Phenotypes related to Leprosy 3:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.33 CCR6 CD4 CD40LG CD8A IFNG IL10
2 cellular MP:0005384 10.32 CD4 CD40LG CD8A IFNG IL10 IL2
3 homeostasis/metabolism MP:0005376 10.25 CCR6 CD4 CD40LG IFNG IL10 IL2
4 immune system MP:0005387 10.25 CCR6 CD4 CD40LG CD8A IFNG IL10
5 cardiovascular system MP:0005385 10.22 CCR6 CD40LG IFNG IL10 IL2 LRRK2
6 endocrine/exocrine gland MP:0005379 10.18 CD4 CD40LG CD8A IFNG IL10 IL2
7 mortality/aging MP:0010768 10.17 CD4 CD40LG CD8A IFNG IL10 IL2
8 digestive/alimentary MP:0005381 10.1 CD4 IFNG IL10 IL2 NOD2 SLC11A1
9 integument MP:0010771 10.02 CD4 CD40LG CD8A IFNG IL10 LRRK2
10 nervous system MP:0003631 9.9 CCR6 CD4 CD40LG CD8A IFNG IL10
11 neoplasm MP:0002006 9.86 IFNG IL10 IL2 MLLT1 SDHD SLC11A1
12 no phenotypic analysis MP:0003012 9.5 CD4 IFNG IL10 IL2 LRRK2 PRKN
13 normal MP:0002873 9.32 CCR6 CD4 CD8A IFNG IL10 LRRK2

Drugs & Therapeutics for Leprosy 3

Drugs for Leprosy 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dapsone Approved, Investigational Phase 4 80-08-0 2955
2
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
3 Vitamins Phase 4
4 Antibiotics, Antitubercular Phase 4
5 Antiprotozoal Agents Phase 4
6 Antiparasitic Agents Phase 4
7 Antimalarials Phase 4
8 Anti-Bacterial Agents Phase 4
9 Anti-Infective Agents Phase 4
10 Immunosuppressive Agents Phase 4
11 Immunologic Factors Phase 4
12 Angiogenesis Inhibitors Phase 4
13
Amitriptyline Approved Phase 3 50-48-6 2160
14
Tramadol Approved, Investigational Phase 3 27203-92-5 33741
15
Perphenazine Approved Phase 3 58-39-9 4748
16
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
17
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
18
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
19
Clarithromycin Approved Phase 2, Phase 3 81103-11-9 84029
20
Streptomycin Approved, Vet_approved Phase 2, Phase 3 57-92-1 19649
21
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181 3911
22
Goserelin Approved Phase 3 65807-02-5 5311128 47725
23
Miltefosine Approved, Investigational Phase 3 58066-85-6 3600
24
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
25
Infliximab Approved Phase 3 170277-31-3
26
Clofazimine Approved, Investigational Phase 2, Phase 3 2030-63-9 2794
27
Bedaquiline Approved Phase 2, Phase 3 843663-66-1
28
Linezolid Approved, Investigational Phase 2, Phase 3 165800-03-3 441401
29
Moxifloxacin Approved, Investigational Phase 2, Phase 3 354812-41-2, 151096-09-2 152946
30
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
31 Tocotrienol Investigational Phase 3 6829-55-6
32 Antidepressive Agents Phase 3
33 Narcotics Phase 3
34 Analgesics, Non-Narcotic Phase 3
35 Adrenergic Agents Phase 3
36 Analgesics Phase 3
37 Psychotropic Drugs Phase 3
38 Analgesics, Opioid Phase 3
39 Antipsychotic Agents Phase 3
40 Amitriptyline, perphenazine drug combination Phase 3
41 Antidepressive Agents, Tricyclic Phase 3
42 Hormones Phase 3
43 Antineoplastic Agents, Hormonal Phase 3
44 Cyclosporins Phase 2, Phase 3
45 Antifungal Agents Phase 2, Phase 3
46 Calcineurin Inhibitors Phase 2, Phase 3
47 Adjuvants, Immunologic Phase 3
48 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
49 Cytochrome P-450 CYP3A Inhibitors Phase 2, Phase 3
50 Androgens Phase 3

Interventional clinical trials:

(show top 50) (show all 70)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
2 Evaluating Immunogenicity and Safety Effect on Combined Immune Effect of EV71 Inactivated Vaccine and HepB、MPSV-A、MR、JE-L:A Multi-center Randomized Controlled Trial Unknown status NCT03519568 Phase 4
3 Effect of Additional Clofazimine on ENL Reactions in Leprosy Completed NCT01290744 Phase 4 Clofazimine;Placebo
4 Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers Completed NCT01165840 Phase 4 Dapsone
5 Independent Study to Establish the Efficacy of the Six Doses Uniform MDT Regimen (U-MDT) for Leprosy Patients Completed NCT00669643 Phase 4 PB 6 doses - Rifampicin and Dapsone;PB 6 doses - Rifampicin, Clofazimine and Dapsone;MB 12 doses - Rifampicin, Clofazimine and Dapsone;MB 6 doses - Rifampicin, Clofazimine and Dapsone
6 Use of Thalidomide in Chronic Uveitis Terminated NCT00314665 Phase 4 Thalidomide
7 Treatment of Neuropathic Pain in Leprosy: a Randomized Double Blind Controlled Study Unknown status NCT03324035 Phase 3 Amitriptyline;Placebo oral capsule;Tramadol
8 Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
9 A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions Completed NCT00919815 Phase 2, Phase 3 Ciclosporin;Prednisolone
10 Efficacy and Safety of Immunomodulator (Mycobacterium w.) as an Adjunct Therapy in Category I Pulmonary Tuberculosis and Along With Assessment of Immunological Parameters Completed NCT00341328 Phase 3
11 Efficacy and Safety Study of Immunomodulator (Mycobacterium w) as an Adjunct Therapy in Category-II Pulmonary Tuberculosis Along With Assessment of Immunological Parameters Completed NCT00265226 Phase 3
12 Randomized Controlled Trial Comparing Efficacy of 8 Weeks Treatment With Clarithromycin and Rifampicin Versus Streptomycin and Rifampicin for Buruli Ulcer (M. Ulcerans Infection) Completed NCT01659437 Phase 2, Phase 3 Clarithromycin Extended Release;Streptomycin intramuscular injection
13 A Double Blinded Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients With Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation Completed NCT00004635 Phase 3 Thalidomide;leuprolide acetate;goserelin
14 A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL Completed NCT02193022 Phase 3 Miltefosine
15 Phase 2 Study for Infrared Thermometry Used by Diabetic Patients at Home Completed NCT00289497 Phase 2, Phase 3
16 Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar Recruiting NCT03662022 Phase 3 Rifampicin
17 Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia Patients of Pakistan Recruiting NCT03651102 Phase 2, Phase 3 Thalidomide Oral Product
18 Thalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research Network Recruiting NCT03221166 Phase 3 Thalidomide;Infliximab
19 Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial Not yet recruiting NCT03942354 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Directly observed therapy (DOT)
20 Economic Evaluation of New MDR TB Regimens (PRACTECAL EE) Not yet recruiting NCT04207112 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Standard Drugs
21 Pharmacokinetics and Pharmacodynamics Sub-study for TB-PRACTECAL Clinical Trial ( PRACTECAL-PKPD) Not yet recruiting NCT04081077 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine
22 To Study the Efficacy of Teriparatide in Improving Remodeling of Foot Bones in Chronic Charcot Neuroarthropathy in Patients With Diabetes Mellitus. Unknown status NCT02023411 Phase 2 Teriparatide
23 Phase 2 Randomized, Multicenter, Safety and Efficacy Trial to Evaluate Different Oral Benznidazole Monotherapy and Benznidazole/E1224 Combination Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Unknown status NCT03378661 Phase 2 Benznidazole;E1224;E1224 Placebo;Benznidazole Placebo
24 Two New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Phase II Study in a Leprosy-Endemic Region Completed NCT00128193 Phase 2
25 Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide Completed NCT00162760 Phase 2 Thalidomide
26 A Pilot Study Assessing the Efficacy and Safety of Ciclosporin as a Second -Line Drug in Patients With Type 1 Reactions Who Have Not Responded to a 12 Week Course of Prednisolone. Completed NCT00919451 Phase 2 ciclosporin
27 A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone. Completed NCT00919542 Phase 2 Ciclosporin;prednisolone
28 A Pilot Double Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled With Standard Prednisolone, and Comparing a Group Treated With Ciclosporin to a Group Treated With Additional Steroid Only. Completed NCT00919776 Phase 2 prednisolone;ciclosporin
29 A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas Completed NCT00047879 Phase 2 Thalidomide
30 An Open-Label Study to Evaluate the Efficacy and Safety of TMC207 in Subjects With Multibacillary Leprosy Recruiting NCT03384641 Phase 2 Bedaquiline 200 mg
31 A Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of CC-11050 in Nepalese Patients With Erythema Nodosum Leprosum Recruiting NCT03807362 Phase 2 CC-11050
32 Phase 2 Study of Clofazimine for the Treatment of Pulmonary Mycobacterium Avium Disease Recruiting NCT02968212 Phase 2 Clofazimine
33 A Phase 1b / 2a, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Adult Participants in Areas Endemic for Leprosy Not yet recruiting NCT03947437 Phase 1, Phase 2
34 Umbilical Cord Serum Versus Conventional Eyedrops In Treatment of Moderate To Severe Dry Eye Disease: A Randomized Clinical Trial Not yet recruiting NCT04217785 Phase 1, Phase 2 Optive, Ophthalmic Solution;Genteal lubricant gel
35 Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain Terminated NCT00301405 Phase 2 Thalidomide
36 A Phase II, Open-Label, Single Center Pilot Study to Determine the Safety and Efficacy of THALOMID (Thalidomide) in Patients With Chronic Pancreatitis. Terminated NCT00469703 Phase 2 Thalidomide
37 A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of Clofazimine (CFZ) in Cryptosporidiosis Terminated NCT03341767 Phase 2 Clofazimine;Placebo
38 The Effects of Virgin Coconut Oil Supplementation on Oxidative Stress and Treatment Response Among Hansen's Disease Patients on Multi-Drug Therapy: A Pilot Study Withdrawn NCT01885611 Phase 1, Phase 2
39 Proposal Evaluation and Intervention Through Prevention of Disability in Leprosy Patients Completed NCT01006759 Phase 1
40 Phase I Study to Evaluate New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Completed NCT01920750 Phase 1
41 A Phase 1, Open Label, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Subjects Completed NCT03302897 Phase 1
42 Pharmacokinetics and Distribution of Dapsone (DDS) in Leucocytes After Single-dose and Multiple-dose Administration in Healthy Subjects Genotyped for CYP2C9 and NAT2 and in Patients With Autoimmune Bullous Dermatoses Completed NCT02493283 Phase 1 Dapsone single dose;Dapsone multiple dose
43 A Phase I Study of the Safety and Immunogenicity of BCG (Bacille Calmette-Guerin) Vaccine Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG. Completed NCT00654316 Phase 1
44 Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery Completed NCT00816426 Phase 1 Rifampicin;Isoniazid;Pyrazinamide;Kanamycin;Moxifloxacin
45 A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Infected With HIV Completed NCT00395720 Phase 1
46 A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis. Completed NCT00456183 Phase 1
47 Montelukast as an Alternative or Supplementary Treatment in ENL Reaction in Leprosy Unknown status NCT00406861 montelukast in treatment of ENL reaction
48 Evaluation of Low Level Laser Therapy Effects in Peripheral Nerves Patient Affected With Leprosy : Randomized Controlled Trial Unknown status NCT03072004
49 Molecular Epidemiology of Leprosy in Colombia Completed NCT00138437
50 Molecular Epidemiology of Leprosy - Philippines Completed NCT00315809

Search NIH Clinical Center for Leprosy 3

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Thalidomide

Cochrane evidence based reviews: leprosy

Genetic Tests for Leprosy 3

Genetic tests related to Leprosy 3:

# Genetic test Affiliating Genes
1 Leprosy 3 29 TLR2

Anatomical Context for Leprosy 3

The Foundational Model of Anatomy Ontology organs/tissues related to Leprosy 3:

19
Superficial Peripheral Nerves, Skin, Mucous Membranes Of The Upper Respiratory Tract, Anterior Chamber Of The Eyes, Testes

MalaCards organs/tissues related to Leprosy 3:

40
Skin, Testes, T Cells, Eye, Bone, Liver, Monocytes

Publications for Leprosy 3

Articles related to Leprosy 3:

(show top 50) (show all 20202)
# Title Authors PMID Year
1
No involvement of non-synonymous TLR2 polymorphisms in Japanese leprosy patients. 61 56 6
19111445 2009
2
TLR2 Arg677Trp polymorphism in leprosy: revisited. 6 61 56
15726416 2005
3
Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. 61 6 56
12646604 2003
4
Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. 6 56 61
11476982 2001
5
Polymorphism N248S in the human Toll-like receptor 1 gene is related to leprosy and leprosy reactions. 6 61
19456232 2009
6
Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. 56 61
18177245 2008
7
The polymorphism P315L of human toll-like receptor 1 impairs innate immune sensing of microbial cell wall components. 6
17475868 2007
8
A family of human receptors structurally related to Drosophila Toll. 56
9435236 1998
9
The implementation of an integrated e-leprosy framework in a leprosy control program at primary health care centers in Indonesia. 61
32497853 2020
10
A critical comparative ethnographic study of courtesy stigma in two leprosy-impacted communities in Indonesia. 61
31971879 2020
11
'Zero Leprosy' and other endgame strategies: Rhetoric vs. realism in public health campaigns. 61
32202468 2020
12
Metabolism and interactions of antileprosy drugs. 61
32339493 2020
13
Immune Complex-Driven Generation of Human Macrophages with Anti-Inflammatory and Growth-Promoting Activity. 61
32434940 2020
14
Oral candida prevalence and species specificity in leprosy. 61
31796204 2020
15
Hematological alterations in lepromatous leprosy: A cross-sectional observational study. 61
31796205 2020
16
Current updates on dental perspectives of leprosy - Revisited. 61
31813526 2020
17
Update on the use of dapsone in dermatology. 61
31909480 2020
18
Sarcoidosis with cutaneous perineural granulomas and neurological manifestations: A potential mimicker of leprosy. 61
32022940 2020
19
Macular hypopigmentation, hair loss and follicular spongiosis: A distinct clinicopathological entity. 61
30688218 2020
20
Epidemiological aspects of leprosy. 61
31806242 2020
21
Epidemiological profile and severity of erythema nodosum leprosum in Brazil: a cross-sectional study. 61
32358972 2020
22
Leprosy: Clinical aspects and diagnostic techniques. 61
32229279 2020
23
Leprosy: Treatment and management of complications. 61
32244016 2020
24
Pathological, ultrasonographic, and electrophysiological characterization of clinically diagnosed cases of pure neuritic leprosy. 61
32250546 2020
25
Nutritional status and morbidity profile of children with leprosy contact in a rural community. 61
32576099 2020
26
[When a wrist sprain leads to diagnosing leprosy - a case report]. 61
32531791 2020
27
Logotherapy towards self-esteem of leprosy patients at Tadjuddin Chalid Hospital in Makassar City. 61
32545100 2020
28
Response to "Three drugs are unnecessary for treating paucibacillary leprosy-A critique of the WHO guidelines". 61
32497033 2020
29
Novel PCR primers for improved detection of Mycobacterium leprae and diagnosis of leprosy. 61
31981442 2020
30
Structure, stability and chaperone function of Mycobacterium leprae Heat Shock Protein 18 are differentially affected upon interaction with gold and silver nanoparticles. 61
32084461 2020
31
Clofazimine: an old drug for never-ending diseases. 61
32476494 2020
32
The immunology of other mycobacteria: M. ulcerans, M. leprae. 61
32100087 2020
33
Characteristics of Oral Lesions in Patients With Hansen Disease. 61
32574720 2020
34
Treatment of histoid leprosy: a lack of consensus. 61
32544270 2020
35
Analysis of HLA-G protein expression in leprosy. 61
32556498 2020
36
[Erratum to: Leprosy in Amazonas-impressions of the National Leprosy Program]. 61
32394078 2020
37
Case Report: Leprosy Osteoarticular Alterations Mimicking Rheumatoid Arthritis. 61
32228782 2020
38
Erythroderma: a prospective study of 309 patients followed for 12 years in a tertiary center. 61
32555205 2020
39
Genotyping of Mycobacterium leprae for understanding the distribution and transmission of leprosy in endemic provinces of China. 61
32553715 2020
40
Oro-facial manifestations in lepromatous leprosy patients in Central India: clinical findings from a cross-sectional study. 61
31435822 2020
41
Real-time PCR-based quantitation of viable Mycobacterium leprae strain from clinical samples and environmental sources and its genotype in multi-case leprosy families of India. 61
32577954 2020
42
The risk of leprosy in patients using immunobiologics and conventional immunosuppressants for the treatment of dermatological and rheumatological diseases: A cohort study. 61
32564427 2020
43
A Case of Dapsone Hypersensitivity Syndrome in an Indian Leprosy Patient: Retrospective Screening Reveals the Genetic Connection with HLA-B*13:01. 61
32535989 2020
44
Human genetics of Buruli ulcer. 61
32266523 2020
45
Developing Feasible, Locally Appropriate Socioeconomic Support for TB-Affected Households in Nepal. 61
32532101 2020
46
Evaluation of the sub-acute toxicity of Acacia catechu Willd seed extract in a Wistar albino rat model. 61
32169672 2020
47
Mycobacterium lepromatosis genome exhibits unusually high CpG dinucleotide content and selection is key force in shaping codon usage. 61
32512206 2020
48
Caprine nodular thelitis due to Mycobacterium uberis: A series of 26 cases in 11 dairy goat farms in Western France. 61
32540717 2020
49
[Leprosy in Amazonas-impressions of the National Leprosy Program]. 61
32333041 2020
50
Genetics of leprosy: today and beyond. 61
31713021 2020

Variations for Leprosy 3

ClinVar genetic disease variations for Leprosy 3:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TLR2 NM_001318789.2(TLR2):c.2029C>T (p.Arg677Trp)SNV risk factor 6663 rs121917864 4:154626088-154626088 4:153704936-153704936

Copy number variations for Leprosy 3 from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 255081 9 72339785 73251640 Duplication TRPM3 Leprosy

Expression for Leprosy 3

Search GEO for disease gene expression data for Leprosy 3.

Pathways for Leprosy 3

Pathways related to Leprosy 3 according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14 TNF TLR2 SLC11A1 PRKN NOD2 IL2
2
Show member pathways
13.31 TNF NOD2 IL2 IL10 IFNG CD40LG
3
Show member pathways
12.78 TNF LRRK2 IL2 IL10 IFNG CD8A
4
Show member pathways
12.61 TNF IL2 IL10 IFNG CD40LG CD4
5
Show member pathways
12.56 TNF IL2 IL10 IFNG CD4
6
Show member pathways
12.56 TNF TLR2 NOD2 IL2 IL10 IFNG
7 12.52 TNF TLR2 IL2 IL10 IFNG CD8A
8
Show member pathways
12.4 TNF TLR2 IL2 IL10 IFNG CD8A
9
Show member pathways
12.29 TNF IL2 IL10 CCR6
10
Show member pathways
12.28 TLR2 SLC11A1 CD4 CCR6
11
Show member pathways
12.23 TNF TLR2 IL10 IFNG CD40LG
12 12.2 TNF TLR2 NOD2 IL10 IFNG
13
Show member pathways
11.96 IL2 IFNG CD8A CD4
14 11.91 TNF IL2 IL10 IFNG CD8A CD4
15 11.89 TNF TLR2 IL10 IFNG
16
Show member pathways
11.82 TNF TLR2 IL2 IL10 IFNG CD4
17
Show member pathways
11.75 TNF IL2 IFNG CD40LG
18
Show member pathways
11.64 TNF IL2 IFNG CD40LG
19
Show member pathways
11.61 TNF IL2 IFNG CD8A
20 11.53 TNF IL2 IFNG
21 11.5 TNF TLR2 IFNG
22 11.5 TNF TLR2 IL10 IFNG CD40LG
23 11.49 TNF IL2 IFNG
24 11.47 IL2 IL10 IFNG CD4
25 11.38 CD8A CD40LG CD4
26 11.36 TNF IL10 IFNG
27
Show member pathways
11.35 TNF IL2 IL10 IFNG
28 11.31 IL2 IFNG CD40LG
29 11.3 TNF IL2 IL10 IFNG CD8A CD4
30 11.22 IL2 IFNG CD4
31 11.18 IL2 IL10 IFNG
32 11.07 TNF IL2 IL10 IFNG CD8A CD4
33 11.02 TNF IL2 IL10 IFNG CD4

GO Terms for Leprosy 3

Cellular components related to Leprosy 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.46 TNF TLR2 LRRK2 CD4
2 external side of plasma membrane GO:0009897 9.35 TNF CD8A CD40LG CD4 CCR6
3 cell surface GO:0009986 9.1 TNF TLR2 NOD2 CD40LG CD4 CCR6

Biological processes related to Leprosy 3 according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.2 TNF TLR2 SLC11A1 PRKN NOD2 IL2
2 positive regulation of gene expression GO:0010628 10.08 TNF TLR2 SLC11A1 PRKN IFNG
3 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.92 TNF PRKN NOD2 CD4
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 TNF TLR2 NOD2 CD40LG
5 negative regulation of protein phosphorylation GO:0001933 9.86 PRKN LRRK2 IL2
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 TNF IL2 IFNG
7 cellular response to organic cyclic compound GO:0071407 9.83 TNF NOD2 LRRK2
8 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.82 TNF TLR2 NOD2
9 positive regulation of MAP kinase activity GO:0043406 9.82 TNF NOD2 LRRK2
10 positive regulation of T cell proliferation GO:0042102 9.81 IL2 CD40LG CD4
11 humoral immune response GO:0006959 9.8 TNF IFNG CCR6
12 positive regulation of interleukin-6 production GO:0032755 9.79 TNF TLR2 NOD2
13 positive regulation of phagocytosis GO:0050766 9.76 TNF SLC11A1 IFNG
14 positive regulation of interferon-gamma production GO:0032729 9.74 TNF SLC11A1 IL2
15 positive regulation of interleukin-6 secretion GO:2000778 9.73 TNF TLR2 IFNG
16 positive regulation of programmed cell death GO:0043068 9.69 TNF LRRK2
17 response to molecule of bacterial origin GO:0002237 9.68 TLR2 IL10
18 negative regulation of amyloid-beta clearance GO:1900222 9.68 TNF IFNG
19 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 IL10 IFNG
20 cellular response to manganese ion GO:0071287 9.67 PRKN LRRK2
21 positive regulation of cytokine secretion GO:0050715 9.67 TNF IL10 IFNG
22 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.66 TNF IFNG
23 endothelial cell apoptotic process GO:0072577 9.65 TNF IL10
24 microglial cell activation GO:0001774 9.65 TNF TLR2 IFNG
25 protein localization to mitochondrion GO:0070585 9.63 PRKN LRRK2
26 positive regulation of dendritic cell antigen processing and presentation GO:0002606 9.63 SLC11A1 NOD2
27 positive regulation of interleukin-8 production GO:0032757 9.63 TNF TLR2 NOD2
28 negative regulation of cytokine production involved in immune response GO:0002719 9.61 TNF IL10
29 regulation of immunoglobulin secretion GO:0051023 9.6 TNF CD40LG
30 negative regulation of cytokine secretion involved in immune response GO:0002740 9.59 TNF IL10
31 positive regulation of inflammatory response GO:0050729 9.56 TNF TLR2 IL2 IFNG
32 cytokine secretion involved in immune response GO:0002374 9.55 TLR2 NOD2
33 positive regulation of protein phosphorylation GO:0001934 9.55 TNF LRRK2 IL2 IFNG CD4
34 regulation of synaptic vesicle transport GO:1902803 9.54 PRKN LRRK2
35 positive regulation of interleukin-12 production GO:0032735 9.54 TLR2 IFNG CD40LG
36 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.52 TNF IFNG
37 receptor biosynthetic process GO:0032800 9.51 TNF IL10
38 positive regulation of interleukin-10 production GO:0032733 9.5 TLR2 NOD2 CD40LG
39 positive regulation of vitamin D biosynthetic process GO:0060557 9.43 TNF IFNG
40 positive regulation of nitrogen compound metabolic process GO:0051173 9.4 TNF IFNG
41 immune response GO:0006955 9.32 TNF TLR2 SLC11A1 IL2 IL10 IFNG
42 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.26 TLR2 NOD2 LRRK2 IFNG

Molecular functions related to Leprosy 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Hsp70 protein binding GO:0030544 9.13 PRKN PACRG NOD2
2 cytokine activity GO:0005125 9.02 TNF IL2 IL10 IFNG CD40LG

Sources for Leprosy 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....